For the first time, we elucidate the molecular characteristics of early adaptation and resistance to CDK4/6i + ET, using clinically relevant drug concentrations, in HR+, HER2− breast cancer and identify therapeutic strategies to overcome acquired resistance in this setting. Here, ERBB2 is linked to breast cancer.